An increase in insulin sensitivity and basal beta‐cell function in diabetic subjects treated with pioglitazone in a placebo‐controlled randomized study

Aims  To investigate the effect of treatment with pioglitazone on beta‐cell function and insulin sensitivity in Type 2 diabetes.

[1]  S. Kahn,et al.  Proinsulin as a Marker for the Development of NIDDM in Japanese-American Men , 1995, Diabetes.

[2]  B. Spiegelman,et al.  Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. , 1993, Science.

[3]  M. Matsuda,et al.  PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. , 2001, Diabetes.

[4]  A. Festa,et al.  The relation of proinsulin and insulin to insulin sensitivity and acute insulin response in subjects with newly diagnosed Type II diabetes: the Insulin Resistance Atherosclerosis Study , 1999, Diabetologia.

[5]  T. Funahashi,et al.  Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. , 2001, Diabetes.

[6]  P. Scherer,et al.  The adipocyte-secreted protein Acrp30 enhances hepatic insulin action , 2001, Nature Medicine.

[7]  M. Byrne,et al.  Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. , 1997, The Journal of clinical investigation.

[8]  J. Shaw,et al.  Global and societal implications of the diabetes epidemic , 2001, Nature.

[9]  M. Savage,et al.  Between and within subject variation of the first phase insulin response to intravenous glucose , 1988, Diabetologia.

[10]  M. Matsuda,et al.  Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. , 2001, Diabetes care.

[11]  C. Mathews,et al.  Inheritance of a mitochondrial DNA defect and impaired glucose tolerance in BHE/Cdb rats , 1999, Diabetologia.

[12]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[13]  S. Kahn,et al.  Relationship of proinsulin and insulin with noninsulin-dependent diabetes mellitus and coronary heart disease in Japanese-American men: impact of obesity--clinical research center study. , 1995, The Journal of clinical endocrinology and metabolism.

[14]  D. Porte,et al.  Disproportionate elevation of immunoreactive proinsulin in Type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance , 1987, Diabetologia.

[15]  D. Matthews,et al.  Unbiased and Flexible Iterative Computer Program to Achieve Glucose Clamping , 1989, Diabetes Care.

[16]  R. DeFronzo,et al.  Glucose clamp technique: a method for quantifying insulin secretion and resistance. , 1979, The American journal of physiology.

[17]  Z. Wu,et al.  PPARgamma induces the insulin-dependent glucose transporter GLUT4 in the absence of C/EBPalpha during the conversion of 3T3 fibroblasts into adipocytes. , 1998, The Journal of clinical investigation.

[18]  R. Morrison,et al.  PPAR g Induces the Insulin-dependent Glucose Transporter GLUT 4 in the Absence of C / EBP a During the Conversion of 3 T 3 Fibroblasts Into Adipocytes , 1997 .

[19]  J Auwerx,et al.  PPARalpha and PPARgamma activators direct a distinct tissue‐specific transcriptional response via a PPRE in the lipoprotein lipase gene. , 1996, The EMBO journal.

[20]  J. Levy,et al.  Immunoradiometric assay of insulin, intact proinsulin and 32–33 split proinsulin and radioimmunoassay of insulin in diet-treated Type 2 (non-insulin-dependent) diabetic subjects , 1992, Diabetologia.

[21]  G. Grunberger,et al.  Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. , 2001, Diabetes care.

[22]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. , 1996, Annual review of cell and developmental biology.

[23]  J. Rosenstock,et al.  EFFICACY AND SAFETY OF PIOGLITAZONE IN TYPE 2 DIABETES: A RANDOMISED, PLACEBO‐CONTROLLED STUDY IN PATIENTS RECEIVING STABLE INSULIN THERAPY , 2002, International journal of clinical practice.

[24]  S. Efendić.  Pathogenesis of NIDDM. , 1988, Diabetes research and clinical practice.

[25]  Vincent Lebon,et al.  The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. , 2002, Diabetes.

[26]  T. Funahashi,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Association with Insulin Resistance , 2022 .

[27]  B. Spiegelman,et al.  Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. , 1995, The Journal of clinical investigation.

[28]  S. Aronoff,et al.  Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. , 2000, Diabetes care.

[29]  J. Levy,et al.  Correct Homeostasis Model Assessment (HOMA) Evaluation Uses the Computer Program , 1998, Diabetes Care.

[30]  W. Sheu,et al.  Plasma insulin, C-peptide, and proinsulin concentrations in obese and nonobese individuals with varying degrees of glucose tolerance. , 1993, The Journal of clinical endocrinology and metabolism.

[31]  R. Holman,et al.  UKPDS 26: sulphonylurea failure in non‐insulin‐dependent diabetic patients over six years , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[32]  M. Matsuda,et al.  Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. , 2002, Diabetes care.

[33]  J. S. St. Peter,et al.  A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. , 2002, Diabetes care.

[34]  Y. Yamasaki,et al.  Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan. , 1997, The Tohoku journal of experimental medicine.